Lenalidomida Qilu

Lenalidomide, the active ingredient in Lenalidomida Qilu, is an immunomodulatory agent (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients under specialist supervision.

GNH USA supplies Lenalidomida Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenalidomida Qilu is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic hematopoietic clones. It is employed in the following approved indications: - Multiple myeloma: improves progression‑free survival and overall response rates when used in combination regimens. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma: contributes to disease control as part of combination therapy.

Lenalidomida Qilu may cause a range of adverse reactions. Patients should be monitored regularly for both common and serious events.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: lowered platelet levels, may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach, sometimes with vomiting. - Diarrhea: loose stools, may lead to dehydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophils requiring hospitalization. - Severe thrombocytopenia: dangerous bleeding events. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevation. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, clinicians should assess baseline parameters and educate patients on safety measures. - Blood count monitoring: perform complete blood counts weekly during the first two cycles. - Thromboembolic risk assessment: consider prophylactic anticoagulation in high‑risk patients. - Pregnancy avoidance: enforce strict contraception; drug is teratogenic. - Renal function adjustment: dose may need modification in moderate to severe renal impairment. - Store below 25°C: keep in original container, protect from moisture and direct sunlight.

Lenalidomida Qilu can interact with several medicines; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower lenalidomide exposure. - Concurrent use with other immunomodulatory agents: may amplify hematologic toxicity. - Anticoagulants combined with high thrombotic risk: heightened chance of clot formation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): modestly increase drug levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can worsen renal function. - Live vaccines: reduced efficacy; avoid during treatment.